Т Л	<b>isava</b>	VAMAR LISO (CE) Code : 4450		
rsior	n: 15 Revi	sion: 02/01/2023	Previous revision: 29/04/2020	Date of printing: 02/01/20
tures.	This product does not me	et the classification criteria of Re	), a safety data sheet (SDS) must be provided fo gulation (EC) No. 1272/2008 (CLP).Therefore, t each section are not applicable.	
			AND OF THE COMPANY/UNDERTAKING	
1	PRODUCT IDENTIFIE	ER:		
	VAMAR LISO (CE)			
	Code: 4450			
2			ICE OR MIXTURE AND USES ADVISED A	<u>GAINST:</u>
l	Liquid paint.	echnical functions): [] In	dustrial [X] Professional [X] Consumers	
ſ	Sectors of use:			
	Consumer uses (SU21)	,		
l	Professional uses (SU2	2),		
l	Uses advised against	-		
ſ	consistent with the safe		ct can be used in ways other than the identified u	uses, but all uses have to be
			use, according to Annex XVII of Regulation	(EC) No. 1907/2006:
	Not restricted.			<u> </u>
3	DETAILS OF THE SU	IPPLIER OF THE SAFETY DA	TA SHEET:	
	PINTURAS ISAVAL, S.I		~ ~ ~	
l			oja del Turia (Valencia) ESPAÑA	
ĺ		1640001 - Fax: +34 96 1640002 e person responsible for the S		
[	atencionalcliente@isava		alety Data Sheet.	
4	EMERGENCY TELEF			
l	+34 96 1640001 8:00-1	3:00 h.		
OTION	N 2 : HAZARDS IDENTIF	CATION		
1	CLASSIFICATION OF	THE SUBSTANCE OR MIXT	URE:	
[	This product is not class	ified as dangerous, in accordance	ce with Regulation (EU) No. 1272/2008~2021/84	9 (CLP).
	under ordinary conditior		according to the Regulation (EC) no. 2020/878. ochemical, health safety or environmental hazar st.	
2	LABEL ELEMENTS:			
1		equire pictograms, in accordance	with Regulation (EU) No. 1272/2008~2021/849	(CLP).
ſ	- Hazard statements:			
l	None.	nonto:		
ſ	- Precautionary stater P102	Keep out of reach of children.		
	P262	Do not get in eyes, on skin, or o	n clothina.	
	P271	Use only outdoors or in a well-ve		
1	P273	Avoid release to the environment	ıt.	
ĺ	- Supplementary state			
ĺ	EUH208		loro-2-methyl-2H-isothiazolin-3-one [EC 247-50 enzisothiazol-3(2H)-one. May produce an allergi	
	- Substances that con	tribute to classification:	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
		qual to or higher than the limit for	the name.	
3	OTHER HAZARDS:			
			ay contribute to the overall hazards of the mixtu	re:
l	- Other physicochemic			
ſ	No other relevant adver			
1	- Other adverse huma No other relevant adver			
	- Other negative envir			
		ances that fulfil the PBT/vPvB crit	eria.	
	Does not contain substa			
	Endocrine disrupting	<u>properties:</u>		

Not applicable (mixture).         2       MXTURES: The product is a mixture.         3       MXININES: The product is a mixture.         3       Solution of Calcum catoronate in aqueous media.         3       MXININGREDIENTS: Substances taking part in a parcentage higher than the exemption limit:         3       Substances taking part in a parcentage higher than the exemption limit:         3       C < 0.05 %         12       Derizonizatis/32H; one ISAN same. 11471 (mature Xait 14400 (M=10) ISAN same.11471 (mature Xait 14400 (M=10) ISAN same.114410 (M=100) IAquate Chronic 1:H410 (M=100) IEUH071 ISAN sens.         1       Imputties: Does not contain other components or impurities which will influence the classification of the product.         1       Imputties: None.       Doffset Sc = 00 Substance Sc =	ersio	n: 15 Re	vision: 02/01/2023	Previous revis	ion: 29/04/2020	Date of printing: 02/01/20			
1.1       EUBSTANCES: Not applicable (mixture).         3.2       MMXTURES: This product is a mixture. Chemical description: Solution of Calcum carbonate in aqueous media. HAZARDUSI NOREPLICIENTS: Substances taking part in a percentage higher than the exemption limit: C < 0,005 %		IDD 3: COMPOSITION/INFORMATION ON INGREDIENTS         SUBSTANCES:         Not applicable (inkure).         IDD 3: COMPOSITION/INFORMATION ON INGREDIENTS         SUBSTANCES:         This product is a mixture.         Chemical description:         Solution of Calcium carbonate in squeeous media.         HAZARDOUS INGREDIENTS:         Substances taking part in a percentage higher than the exemption limit:         C < 0.005 %							
Not applicable (mixture).           12         MIX_IVES:           This product is a mixture.         Chemical description:           Solution of Calcium carbonate in aqueous media.         HAX_REPOILS INGREDENTS:           Substances taking part in a percentage higher than the exemption limit.         C < 0.0 %				0					
22       MixTURES: This product is a mixture. Chamical description: Solution of Calcium carbonate in aqueous media. HAZARDOUS.INGREDIENTS: Substances laking part in a percentage higher than the examption limit.       REACH       Skin Sens. 1.H3 C < 0.05 %			re).						
Chemical description:       Solution of Calcium cathonals in aqueous media.         HAZARDOUS. INGREDIENTS:       Substances taking part in a prenerage higher than the exemption limit:         C < 0.06 %	3.2		,						
Solution of Calcium carbonate in a geneous media.         HAZARPOUSI INGREDENTS:         Substances taking part in a percentage higher than the exemption limit:         C < 0.05 %									
HAZARDOUS INGREDIENTS: I         Substances taking part in a percentage higher than the exemption limit:         C < 0,05 %									
Substances taking part in a percentage higher than the exemption limit:         C < 0.05 %			-						
C + 0.0     C - 0.02     C - 0.015     C - 0.0015     C - 0.001     C - 0.0015     C - 0.0015     C - 0.0015     C - 0.0015     C - 0.001				ne exemption limit:					
C = C = 0.0015 %       C = C = 0.0015 %       ATP13 Set 0.0015 %         C < 0.0015 %		C < 0,05 %							
[Skin Sens: 1:H317   Aquatic Acute 1:H400 (M=10)         C < 0,015 %						C 20,05			
A      A					Lye Dam. 1.11510				
A      A		C < 0,0015 %	Reaction mass of 5-chloro-2-m	nethyl-2H-isothiazolin-3-one	[EC 247-500-7]	ATP13 Skin Corr. 1C, H31			
CLAS: 50940-94-9; EC: 011-341-5     CLP: Danger: Acute Tox. (nh; 2:H330   Acute Tox. (skin) 2:H310   Acute Tox. (skin) 2:H310   Acute Tox. (rail) 3:H301   Skin Corr. 1C:H314   Eye Dam. 1:H318   Aquatic Acute Tox. (rail) 3:H301   Skin Corr. 1C:H314   Eye Dam. 1:H318   Aquatic Acute Tox. (rail) 3:H301   Skin Corr. 1C:H314   Eye Dam. 1:H318   Aquatic Acute Tox. (rail) 3:H301   Skin Corr. 1C:H314   Eye Dam. 1:H318   Aquatic Acute Tox. (rail) 3:H301   Skin Corr. 1C:H314   Eye Dam. 1:H318   Aquatic Acute Tox. (rail) 3:H301   Skin Corr. 1C:H314   Eye Dam. 1:H318   Aquatic Acute Tox. (rail) 3:H301   Skin Corr. 1C:H314   Eye Dam. 1:H318   Aquatic Acute Tox. (rail) 3:H301   Skin Corr. 1C:H314   Eye Dam. 1:H318   Aquatic Acute Tox. (rail) 3:H301   Skin Corr. 1C:H314   Eye Dam. 1:H318   Aquatic Acute Tox. (rail) 3:H301   Skin Corr. 1:H310   Aquatic Acute Tox. (rail) 3:H3161   Skin Corr. 1:H310   Aquatic Acute Tox. (rail) 3:H310   Skin Corr. 1:H310   Aquatic Acute Tox. (rail) 3:H310   Skin Corr. 1:H310   Aquatic Acute Tox. (rail) 3:H310   Skin Corr. 1:H310   Aquatic Acute Tox. (rail) 3:H3101   Skin Corr. 1:H310   Aquatic Acute Tox. (rail) 3:H310   Skin Corr. 1:H310   Aquatic Acute Tox. (rail) 3:H310   Skin Corr. 1:H310   Aquatic Acute Tox. (rail) 3:H310   Skin Corr. 1:H310   Corr. 1:H310			and 2-methyl-2H-isothiazol-3-c	one [EC 220-239-6] (3:1)		C ≥0,6 Skin Irrit. 2, H31			
(oral) 3:H301 [ Skin Corr. 1C:H314 [ Eye Dam. 1:H318   Aquatic Acute       C:200         1:H400 (M=100) [ Aquatic Chronic 1:H410 (M=100) [ EUH071 ] Skin Sens.       Dest Mit 2, 40         1:A:H317 (Note B)       Dist Sens.       Dist Sens.         Impurities:       Does not contain other components or impurities which will influence the classification of the product.       Similar Sense.         Stabilizers:       None.       Reference to other sections:       For more information, see sections 8, 11, 12 and 16.         SUBSTANCES OF VERY HIGH CONCERN (SVHC):       List updated by ECHA on 1006/202.       Substances SVHC subject to authorisation, included in Annex XIV of Regulation (EC) no. 1907/2006:         None.       Substances SVHC candidate to be included in Annex XIV of Regulation (EC) no. 1907/2006:       None.         SUBSTANCES.       Description of First-Al D MeASURES:       Description of First-Al D MeASURES:         Color 4: FIRST AID MEASURES:       Description of first-aid measures       Should there be any symptoms persist, tansfer the person affected are with plenty of clean, transfer the person affected are with plenty of clean, transfer the person affected are with plenty of clean, tresh ware, normal conditions of use.         Skin:       It is not expected that symptoms will occur under frequed auth plenty of clean, fresh water, holding the symptoms of use.         Skin:       It is not expected that symptoms will occur under frequed auth plenty of clean, fresh water, holding the symptoms of use.         Skin: <td></td> <td></td> <td></td> <td></td> <td>PH310   Acute Tox</td> <td>0,06 % ≤ C &lt; 0,6 Eve Dam 1 H3</td>					PH310   Acute Tox	0,06 % ≤ C < 0,6 Eve Dam 1 H3			
1AH317 (Note B)     1			(oral) 3:H301   Skin Corr. 1C:H	1314   Eye Dam. 1:H318   Ac	uatic Acute	C ≥0,6			
Imputities:         Does not contain other components or impurities which will influence the classification of the product.           Stabilizers:         None.           Reference to other sections:         For more information, see sections 8, 11, 12 and 16.           SUBSTANCES OF VERY HIGH CONDERN (SVHC):         List updated by ECHA on 10/06/2022.           Substances SVHC subject to authorisation. included in Annex XIV of Regulation (EC) no. 1907/2006; None.         Substances SVHC candidate to be included in Annex XIV of Regulation (EC) no. 1907/2006; None.           Substances SVHC audicate to be included in Annex XIV of Regulation (EC) no. 1907/2006; None.         Substances SVHC candidate to be included in Annex XIV of Regulation (EC) no. 1907/2006; None.           Substances SVHC andidate to be included in Annex XIV of Regulation (EC) no. 1907/2006; None.         Substances SVHC andidate to Be included in Annex XIV of Regulation (EC) no. 1907/2006; None.           Substances SVHC andidate to Be included in Annex XIV of Regulation (EC) no. 1907/2006; None.         Substances SVHC andidate to Be included in Annex XIV of Regulation (EC) no. 1907/2006; None.           SUBSTANCES:         Does not contain substances that fulfil the PBT/vPvB criteria.         ECTION 4: FIRST AID MEASURES           11         DESCRIPTION OF FIRST AID MEASURES:         Seek medical attention.Never give anything by mouth to an unconscious person.           Route of exposure         Symptoms and effects, acute and delayed         Description of first-aid measures           Inhalation: <t< td=""><td></td><td></td><td></td><td>onic 1:H410 (M=100)   EUH(</td><td>071   Skin Sens.</td><td>0,06 % ≤ C &lt; 0,6</td></t<>				onic 1:H410 (M=100)   EUH(	071   Skin Sens.	0,06 % ≤ C < 0,6			
Impurities:           Does not contain other components or impurities which will influence the classification of the product.           Stabilizers:           None.           Reference to other sections:           For more information, see sections 8, 11, 12 and 16.           SUBSTANCES OF VERY HIGH CONCERN (SVHC):           List updated by ECHA on 10/06/2022.           Substances SVHC subject to authorisation, included in Annex XIV of Regulation (EC) no. 1907/2006; None.           Substances SVHC candidate to be included in Annex XIV of Regulation (EC) no. 1907/2006; None.           PERSISTENT, BIOACCUMULABLE AND TOXIC PBT, OR VERY PERSISTENT AND VERY BIOACCUMULABLE VPVB SUBSTANCES:           Does not contain substances that fulfil the PBT/VPVB criteria.           ECTION 4: FIRST AID MEASURES:           Image: Symptoms any occur after exposure, so that in case of direct exposure to the product, when in doubt, or when symptoms persist, seek medical attention Never give anything by mouth to an unconscicus person.           Route of exposure         Symptoms and effects, acute and delayed         Description of first-aid measures           Inhalation:         It is not expected that symptoms will occur under normal conditions of use.         Remove contact lenses.Rines eyes copiously by trigation with plenty of cold or lukewarm water an peutra alsop, or use a subtable skin cleanser.           Skin:         It is not expected that symptoms will occur under normal conditions of use.         Remove contact lenses.Rinse eyes copiousl						Skin Sens. 1A, H3 C ≥0.0015			
Dees not contain other components or impurities which will influence the classification of the product. Stabilizers: None.           Reference to other sections: For more information, see sections 8, 11, 12 and 16. SUBSTANCES OF VERY HIGH CONCERN (SVHC): List updated by ECHA on 10/06/2022. Substances SVHC subject to authorisation, included in Annex XIV of Regulation (EC) no. 1907/2006; None.           Substances SVHC candidate to be included in Annex XIV of Regulation (EC) no. 1907/2006; None.         Desc not contain substances for the patient of the patient o		Impurities:							
None:       Reference to other sections:         For more information, see sections 8, 11, 12 and 16.       SUBSTANCES OF VERY HIGH CONCERN (SVHC):         List updated by ECHA on 10/06/2021.       Substances SVHC subject to authorisation, included in Annex XIV of Regulation (EC) no. 1907/2006:         None.       Substances SVHC candidate to be included in Annex XIV of Regulation (EC) no. 1907/2006:         None.       PERSISTENT. BIOACCUMULABLE AND TOXIC PBT, OR VERY PERSISTENT AND VERY BIOACCUMULABLE VPVB         SUBSTANCES:       Does not contain substances that fulfil the PBT/PVB criteria.         ECTION 4: FIRST AID MEASURES       Description OF FIRST AID MEASURES:         Description OF FIRST AID MEASURES:       Symptoms may occur after exposure, so that in case of direct exposure to the product, when in doubt, or when symptoms persist, seek medical attention. Never give anything by mouth to an unconscious person.         Route of exposure       Symptoms and effects, acute and delayed       Description of first-aid measures         Inhalation:       It is not expected that symptoms will occur under affected to the open air.       Remove contaminated clothing. Wash thoroughly the affected area with plenty of cold or lukewarm water an normal conditions of use.         Eyes:       It is not expected that symptoms will occur under merve contact lenses. Rinse eyes copiously by mirgiation with plenty of cold or lukewarm water an petural soop, or use a suitable skin cleanser.         10       MOST IMPORTANT SYMPTOMS AND EFFECTS. BOTH ACUTE AND DELAYED:       The main			er components or impurities which	ch will influence the classific	ation of the product.				
Reference to other sections:         For more information, see sections 8, 11, 12 and 16.         SUBSTANCES OF VERY HIGH CONCERN (SVHC):         List updated by ECHA on 10/06/2022.         Substances SVHC subject to authorisation, included in Annex XIV of Regulation (EC) no. 1907/2006; None.         Substances SVHC candidate to be included in Annex XIV of Regulation (EC) no. 1907/2006; None.         PERSISTENT. BIOACCUMULABLE AND TOXIC PBT, OR VERY PERSISTENT AND VERY BIOACCUMULABLE VPVB SUBSTANCES;         Does not contain substances that fulfil the PBT/vPvB criteria.         CCTOM 4: FIRST AD MEASURES         Image: Symptoms may occur after exposure, so that in case of direct exposure to the product, when in doubt, or when symptoms persist, seek medical attention. Never give anything by mouth to an unconscious person.         Route of exposure       Symptoms and effects, acute and delayed       Description of first-aid measures         nhalation:       t is not expected that symptoms will occur under       Should there be any symptoms, transfer the person affected to the open air.         Skin:       t is not expected that symptoms will occur under       Remove contact lenses. Rinse eyes copiously by mirgiation with pelving of odo or lukwarm water an neutral soap, or use a suitable skin cleanser.         Eyes:       t is not expected that symptoms will occur under moreal conditions of use.       Deno induce vomiting, due to the risk of aspiration. Keep the patient at rest.         22       MOST IMPORTANT SYMPTOMS AND EFFECTS. BOTH ACUTE AND									
For more information, see sections 8, 11, 12 and 16.         SUBSTANCES OF VERY HIGH CONCERN (SVHC);         List updated by ECHA on 100/6/2022.         Substances SVHC subject to authorisation, included in Annex XIV of Regulation (EC) no. 1907/2006;         None.         PERSISTENT, BIOACCUMULABLE AND TOXIC PBT, OR VERY PERSISTENT AND VERY BIOACCUMULABLE VPVB         Substances SVHC candidate to be included in Annex XIV of Regulation (EC) no. 1907/2006;         None.         PERSISTENT, BIOACCUMULABLE AND TOXIC PBT, OR VERY PERSISTENT AND VERY BIOACCUMULABLE VPVB         SUBSTANCES:         Does not contain substances that fulfil the PBT/vPvB criteria.         ICTION 4: FIRST AID MEASURES:         Symptoms may occur after exposure, so that in case of direct exposure to the product, when in doubt, or when symptoms persist, seek medical attention.Never give anything by mouth to an unconscious person.         Route of exposure       Symptoms and effects, acute and delayed       Description of first-aid measures         Inhalation:       It is not expected that symptoms will occur under normal conditions of use.       Should there be any symptoms, transfer the person affected to the open air.         Skin:       It is not expected that symptoms will occur under normal conditions of use.       Remove contaminated clothing, Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral scap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under net									
SUBSTANCES OF VERY HIGH CONCERN (SVHC): List updated by ECHA on 10/06/2022.         Substances SVHC subject to authorisation, included in Annex XIV of Regulation (EC) no. 1907/2006; None.         Substances SVHC candidate to be included in Annex XIV of Regulation (EC) no. 1907/2006; None.         PERSISTENT BIOACCUMULABLE AND TOXIC PBT, OR VERY PERSISTENT AND VERY BIOACCUMULABLE VPVB SUBSTANCES:         Does not contain substances that fulfil the PBT/vPvB criteria.         SCTION 4: FIRST AID MEASURES         DESCRIPTION OF FIRST AID MEASURES:         Symptoms may occur after exposure, so that in case of direct exposure to the product, when in doubt, or when symptoms persist, seek medical attention. Never give anything by mouth to an unconscious person.         Route of exposure       Symptoms and effects, acute and delayed       Description of first-aid measures         Inhalation:       It is not expected that symptoms will occur under normal conditions of use.       Should there be any symptoms, transfer the person affected to the open air.         Skin:       It is not expected that symptoms will occur under normal conditions of use.       Remove contact lenses. Rinse eyes copiously by rigition with plenty of cold or likewarm water an neutral soap, or use a suitable skin cleanser.         Eyee:       It is not expected that symptoms will occur under normal conditions of use.       Remove contact lenses. Rinse eyes copiously by rigition with plenty of clean, fresh water, holding the eyelids apart. [firitation persists, consult a physician.         Ingestion:       If swallowed in high doses,									
List updated by ECHA on 10/06/2022.         Substances SVHC subject to authorisation, included in Annex XIV of Regulation (EC) no. 1907/2006;         None.         Substances SVHC candidate to be included in Annex XIV of Regulation (EC) no. 1907/2006;         None.         Substances SVHC candidate to be included in Annex XIV of Regulation (EC) no. 1907/2006;         None.         PERSISTENT.BIOACCUMULABLE AND TOXIC PBT, OR VERY PERSISTENT AND VERY BIOACCUMULABLE VPVB SUBSTANCES:         Does not contain substances that fulfil the PBT/vPvB criteria.         COTION 4: FIRST AID MEASURES         DeSCRIPTION OF FIRST AID MEASURES:         Image: Symptoms and effects, acute and delayed         Perciption of first-aid measures         Inhalation:       t is not expected that symptoms will occur under normal conditions of use.         Skin:       It is not expected that symptoms will occur under normal conditions of use.         Requestion:       It is not expected that symptoms will occur under normal conditions of use.         Requestion:       If is not expected that symptoms will occur under normal conditions of use.         Requestion:       If is not expected that symptoms will occur under normal conditions of use.         Requestion:       If is not expected that symptoms will occur under normal conditions of use.         Requestion:       If swallowed in high doses, may cause poo not induce vorniting, due to the risk of apastrointes				HC).					
Substances SVHC subject to authorisation, included in Annex XIV of Regulation (EC) no. 1907/2006; None.         Substances SVHC candidate to be included in Annex XIV of Regulation (EC) no. 1907/2006; None.         PERSISTENT, BIOACCUMULABLE AND TOXIC PBT, OR VERY PERSISTENT AND VERY BIOACCUMULABLE VPVB SUBSTANCES:         Does not contain substances that fulfil the PBT/vPvB criteria.         ECTION 4: FIRST AID MEASURES         Image: Symptoms may occur after exposure, so that in case of direct exposure to the product, when in doubt, or when symptoms persist, seek medical attention.Never give anything by mouth to an unconscious person.         Route of exposure       Symptoms and effects, acute and delayed       Description of first-aid measures         Inhalation:       It is not expected that symptoms will occur under normal conditions of use.       Should there be any symptoms, transfer the person affected to the open air.         Skin:       It is not expected that symptoms will occur under normal conditions of use.       Remove contact lenses. Rinse eyes copiously by trigation with plenty of cold or lukewarm water an neutral scap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Do not induce vomiting, due to the risk of asstraintestinal disturbances.         12       MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED; The main symptoms and effects are indicated in sections 4.1 and 11.1       It         13       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED; Notes to physician				<u>110j.</u>					
Substances SVHC candidate to be included in Annex XIV of Regulation (EC) no. 1907/2006: None.         PERSISTENT, BIOACCUMULABLE AND TOXIC PBT, OR VERY PERSISTENT AND VERY BIOACCUMULABLE VPVB SUBSTANCES:         Does not contain substances that fulfil the PBT/vPvB criteria.         CCTION 4: FIRST AID MEASURES         DESCRIPTION OF FIRST AID MEASURES:         Symptoms may occur after exposure, so that in case of direct exposure to the product, when in doubt, or when symptoms persist, seek medical attention. Never give anything by mouth to an unconscious person.         Route of exposure       Symptoms and effects, acute and delayed       Description of first-aid measures         Inhalation:       It is not expected that symptoms will occur under normal conditions of use.       Should there be any symptoms, transfer the person affected to the open air.         Skin:       It is not expected that symptoms will occur under normal conditions of use.       Remove contaminated clothing.Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Remove contact lenses.Rinse eyes copiously by trigation with plenty of clean, fresh water, holding the agelids apart. If irritation persists, consult a physician.         1.2       MOST IMPORTANT SYMPTOMS AND EFFECTS. BOTH ACUTE AND DELAYED: The main symptoms and effects are indicated in sections 4.1 and 11.1         8.3       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physi				ded in Annex XIV of Regu	lation (EC) no. 1907/2006	<u>):</u>			
None.       PERSISTENT. BIOACCUMULABLE AND TOXIC PBT, OR VERY PERSISTENT AND VERY BIOACCUMULABLE VPVB         SUBSTANCES:       Does not contain substances that fulfil the PBT/vPvB criteria.         ECTION 4: FIRST AID MEASURES       Image: Contrain substances that fulfil the PBT/vPvB criteria.         ECTION 4: FIRST AID MEASURES       Image: Contrain substances that fulfil the PBT/vPvB criteria.         ECTION 4: FIRST AID MEASURES:       Image: Contrain substances that fulfil the PBT/vPvB criteria.         ECTION 4: FIRST AID MEASURES:       Image: Contrain substances that fulfil the PBT/vPvB criteria.         Route of exposure       Symptoms and effects, acute and delayed       Description of first-aid measures         Inhalation:       It is not expected that symptoms will occur under normal conditions of use.       Should there be any symptoms, transfer the person affected to the open air.         Skin:       It is not expected that symptoms will occur under normal conditions of use.       Remove contantinated clothing.Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Remove contact lenses.Rinse eyes copiously by mirgiation with plenty of cold or lukewarm water, holding the eyelids apart.If irritation persists, consult a physician.         Ingestion:       If swallowed in high doses, may cause aspiration.Keep the patient at rest.         1/2       MOST IMPORTANT SYMPTOMS AND EFFECTS									
PERSISTENT, BIOACCUMULABLE AND TOXIC PBT, OR VERY PERSISTENT AND VERY BIOACCUMULABLE VPVB SUBSTANCES: Does not contain substances that fulfil the PBT/vPvB criteria.         CTION 4: FIRST AID MEASURES:         Image: Symptoms may occur after exposure, so that in case of direct exposure to the product, when in doubt, or when symptoms persist, seek medical attention.Never give anything by mouth to an unconscious person.         Route of exposure       Symptoms and effects, acute and delayed       Description of first-aid measures         Inhalation:       It is not expected that symptoms will occur under normal conditions of use.       Should there be any symptoms, transfer the person affected to the open air.         Skin:       It is not expected that symptoms will occur under normal conditions of use.       Remove contaminated clothing.Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Remove contate lenses.Rinse eyes copiously by migration with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.         1.2       MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED:       The main symptoms and effects are indicated in sections 4.1 and 11.1         1.3       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED:       No		1	candidate to be included in A	nnex XIV of Regulation (E	<u>C) no. 1907/2006:</u>				
SUBSTANCES: Does not contain substances that fulfil the PBT/vPvB criteria.         CCTION 4: FIRST AID MEASURES         L1       DESCRIPTION OF FIRST AID MEASURES: Seek medical attention.Never give anything by mouth to an unconscious person.         Route of exposure       Symptoms and effects, acute and delayed       Description of first-aid measures         Nnhalation:       It is not expected that symptoms will occur under normal conditions of use.       Should there be any symptoms, transfer the person affected to the open air.         Skin:       It is not expected that symptoms will occur under normal conditions of use.       Remove contaminated clothing.Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Remove contact lenses.Rinse eyes copiously by irrigation with plenty of clean, fresh water, holding the eyelids apart.If irritation persists, consult a physician.         Ingestion:       If swallowed in high doses, may cause gastrointestinal disturbances.       Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.         12.3       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient. Antidotes and contraindications:									
Does not contain substances that fulfil the PBT/vPvB criteria.         ECTION 4: FIRST AID MEASURES         1.1       DESCRIPTION OF FIRST AID MEASURES: Symptoms may occur after exposure, so that in case of direct exposure to the product, when in doubt, or when symptoms persist, seek medical attention.Never give anything by mouth to an unconscious person.         Route of exposure       Symptoms and effects, acute and delayed       Description of first-aid measures         Inhalation:       It is not expected that symptoms will occur under normal conditions of use.       Should there be any symptoms, transfer the person affected to the open air.         Skin:       It is not expected that symptoms will occur under normal conditions of use.       Remove contaminated clothing.Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral scap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Remove contact lenses.Rinse eyes copiously by irrigation with plenty of clean, fresh water, holding the eyelids apart.If irritation persists, consult a physician.         Ingestion:       If swallowed in high doses, may cause gastrointestinal disturbances.       Do no induce vomiting, due to the risk of aspiration.Keep the patient at rest.         1.2       MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED: The main symptoms and effects are indicated in sections 4.1 and 11.1       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the			ACCUMULABLE AND TOXIC	FDI, OK VERT FERSIS	IENTAND VERT DIOAC	JUNULADLE VEVD			
4.1       DESCRIPTION OF FIRST AID MEASURES:         Symptoms may occur after exposure, so that in case of direct exposure to the product, when in doubt, or when symptoms persist, seek medical attention.Never give anything by mouth to an unconscious person.         Route of exposure       Symptoms and effects, acute and delayed       Description of first-aid measures         Inhalation:       It is not expected that symptoms will occur under normal conditions of use.       Should there be any symptoms, transfer the person affected to the open air.         Skin:       It is not expected that symptoms will occur under normal conditions of use.       Remove contaminated clothing.Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Remove contact lenses.Rinse eyes copiously by irrigation with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.         Ingestion:       If swallowed in high doses, may cause gastrointestinal disturbances.       Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.         4.2       MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED:       The main symptoms and effects are indicated in sections 4.1 and 11.1         4.3       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED:       Notes to physician:         Treatment should be directed at the control of symptoms and the clinical condition of the patient       Antidotes and c			stances that fulfil the PBT/vPvB	criteria.					
Symptoms may occur after exposure, so that in case of direct exposure to the product, when in doubt, or when symptoms persist, seek medical attention.Never give anything by mouth to an unconscious person.           Route of exposure         Symptoms and effects, acute and delayed         Description of first-aid measures           Inhalation:         It is not expected that symptoms will occur under normal conditions of use.         Should there be any symptoms, transfer the person affected to the open air.           Skin:         It is not expected that symptoms will occur under normal conditions of use.         Remove contaminated clothing.Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.           Eyes:         It is not expected that symptoms will occur under normal conditions of use.         Remove contaminated clothing.Wash thoroughly by irrigation with plenty of clean, fresh water, holding the eyelids apart.If irritation persists, consult a physician.           Ingestion:         If swallowed in high doses, may cause gastrointestinal disturbances.         Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.           4.2         MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED: The main symptoms and effects are indicated in sections 4.1 and 11.1         14.3           4.3         INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient Antidotes and contraindications;	ECTIO	N 4: FIRST AID MEASU	JRES						
Seek medical attention.Never give anything by mouth to an unconscious person.           Route of exposure         Symptoms and effects, acute and delayed         Description of first-aid measures           Inhalation:         It is not expected that symptoms will occur under normal conditions of use.         Should there be any symptoms, transfer the person affected to the open air.           Skin:         It is not expected that symptoms will occur under normal conditions of use.         Remove contaminated clothing.Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.           Eyes:         It is not expected that symptoms will occur under normal conditions of use.         Remove contact lenses. Rinse eyes copiously by irrigation with plenty of clean, fresh water, holding the eyelids apart.If irritation persists, consult a physician.           Ingestion:         If swallowed in high doses, may cause gastrointestinal disturbances.         Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.           4.2         MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED: The main symptoms and effects are indicated in sections 4.1 and 11.1         INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient Antidotes and contraindications:	l.1	DESCRIPTION OF FIRST AID MEASURES:							
Inhalation:       It is not expected that symptoms will occur under normal conditions of use.       Should there be any symptoms, transfer the person affected to the open air.         Skin:       It is not expected that symptoms will occur under normal conditions of use.       Remove contaminated clothing.Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Remove contact lenses.Rinse eyes copiously by irrigation with plenty of clean, fresh water, holding the eyelids apart.If irritation persists, consult a physician.         Ingestion:       If swallowed in high doses, may cause gastrointestinal disturbances.       Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.         4.2       MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED: The main symptoms and effects are indicated in sections 4.1 and 11.1       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient       Antidotes and contraindications:		Symptoms may occur after exposure, so that in case of direct exposure to the product, when in doubt, or when symptoms persist, seek medical attention.Never give anything by mouth to an unconscious person.							
Inhalation:       It is not expected that symptoms will occur under normal conditions of use.       Should there be any symptoms, transfer the person affected to the open air.         Skin:       It is not expected that symptoms will occur under normal conditions of use.       Remove contaminated clothing.Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Remove contaminated clothing.Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Remove contact lenses.Rinse eyes copiously by irrigation with plenty of clean, fresh water, holding the eyelids apart.If irritation persists, consult a physician.         Ingestion:       If swallowed in high doses, may cause gastrointestinal disturbances.       Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.         1.2       MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED:       The main symptoms and effects are indicated in sections 4.1 and 11.1         1.3       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED:       Notes to physician:         Treatment should be directed at the control of symptoms and the clinical condition of the patient       Antidotes and contraindications;		Route of exposure	Symptoms and effects	acute and delayed	Description of first-aid me	asures			
Importation of use.       affected to the open air.         Skin:       It is not expected that symptoms will occur under normal conditions of use.       Remove contaminated clothing.Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Remove contact lenses.Rinse eyes copiously by irrigation with plenty of clean, fresh water, holding the eyelids apart.If irritation persists, consult a physician.         Ingestion:       If swallowed in high doses, may cause gastrointestinal disturbances.       Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.         4.2       MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED: The main symptoms and effects are indicated in sections 4.1 and 11.1       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient         Antidotes and contraindications:       Antidotes and contraindications:			Cympionis and checis,			350105			
Skin:         It is not expected that symptoms will occur under normal conditions of use.         Remove contaminated clothing.Wash thoroughly the affected area with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.           Eyes:         It is not expected that symptoms will occur under normal conditions of use.         Remove contact lenses.Rinse eyes copiously by irrigation with plenty of clean, fresh water, holding the eyelids apart.If irritation persists, consult a physician.           Ingestion:         If swallowed in high doses, may cause gastrointestinal disturbances.         Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.           I.2         MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED: The main symptoms and effects are indicated in sections 4.1 and 11.1         INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient Antidotes and contraindications:		Inhalation:				toms, transfer the person			
normal conditions of use.       affected area with plenty of cold or lukewarm water an neutral soap, or use a suitable skin cleanser.         Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Remove contact lenses.Rinse eyes copiously by irrigation with plenty of clean, fresh water, holding the eyelids apart.If irritation persists, consult a physician.         Ingestion:       If swallowed in high doses, may cause gastrointestinal disturbances.       Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.         I.2       MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED: The main symptoms and effects are indicated in sections 4.1 and 11.1       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient. Antidotes and contraindications:		<u> Clrini</u>			-	thing Mach thoroughly the			
Eyes:       It is not expected that symptoms will occur under normal conditions of use.       Remove contact lenses. Rinse eyes copiously by irrigation with plenty of clean, fresh water, holding the eyelids apart. If irritation persists, consult a physician.         Ingestion:       If swallowed in high doses, may cause gastrointestinal disturbances.       Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.         .2       MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED: The main symptoms and effects are indicated in sections 4.1 and 11.1       .3         .3       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient Antidotes and contraindications:		Skin:	normal conditions of us	symptoms will occur under					
Important conditions of use.       irrigation with plenty of clean, fresh water, holding the eyelids apart.If irritation persists, consult a physician.         Ingestion:       If swallowed in high doses, may cause gastrointestinal disturbances.       Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.         .2       MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED: The main symptoms and effects are indicated in sections 4.1 and 11.1       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient         Antidotes and contraindications:       Antidotes and contraindications:					neutral soap, or use a suit	able skin cleanser.			
Ingestion:       If swallowed in high doses, may cause gastrointestinal disturbances.       Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.         I.2       MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED: The main symptoms and effects are indicated in sections 4.1 and 11.1         I.3       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient Antidotes and contraindications:		Eyes:							
Ingestion:         If swallowed in high doses, may cause gastrointestinal disturbances.         Do not induce vomiting, due to the risk of aspiration.Keep the patient at rest.           4.2         MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED: The main symptoms and effects are indicated in sections 4.1 and 11.1         INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient Antidotes and contraindications:			normal conditions of us	e.					
gastrointestinal disturbances.       aspiration.Keep the patient at rest.         4.2       MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED: The main symptoms and effects are indicated in sections 4.1 and 11.1         1.3       INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient Antidotes and contraindications:		Ingestion:	If swallowed in high do	ses, may cause					
The main symptoms and effects are indicated in sections 4.1 and 11.1           INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED:           Notes to physician:           Treatment should be directed at the control of symptoms and the clinical condition of the patient           Antidotes and contraindications:									
.3 INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED: Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient Antidotes and contraindications:	.2				ELAYED:				
Notes to physician: Treatment should be directed at the control of symptoms and the clinical condition of the patient Antidotes and contraindications:									
Treatment should be directed at the control of symptoms and the clinical condition of the patient Antidotes and contraindications:			NY IMMEDIATE MEDICAL A	ITENTION AND SPECIAL	TREATMENT NEEDED	-			
Antidotes and contraindications:	1.3		directed at the control of come t	mo and the allester	of the nationt				
	1.3	I realment should be		oms and the clinical condition	i oi the patient				
	1.3	Antidotes and contr							
	1.3								

$\prec$	isaval pinturas	VAMAR LISO (CE) Code : 4450		
Version	: 15 Revis	sion: 02/01/2023	Previous revision: 29/04/2020	Date of printing: 02/01/2023
SECTION	5: FIREFIGHTING MEAS	SURES		
5.1	EXTINGUISHING MEE			
		oundings, all extinguishing agent		
5.2		RISING FROM THE SUBSTA		e ande en managerida. O ante en discrida
	nitrogen oxides, sulfur ox hazard to health.	kides, halogenated compounds, l	n, hazardous products may be produced hydrochloric acid.Exposure to combustic	
5.3	ADVICE FOR FIREFIC			
	protective glasses or face	e of fire, heat-proof protective clo e masks and boots.If the fire-pro n a safe distance.The standard E	thing may be required, appropriate inde of protective equipment is not available EN469 provides a basic level of protectio	or is not being used, combat fire from a
	Cool with water the tanks		sources of heat or fire.Bear in mind the	direction of the wind.Do not allow fire-
SECTION	I 6: ACCIDENTAL RELEA	SE MEASURES		
6.1			PMENT AND EMERGENCY PROCE	
			oours.Keep people without protection in o	opposition to the wind direction.
6.2		rains, surface or subterranean w	ater and soil.In the case of large scale s as in accordance with local regulations.	pills or when the product contaminates
6.3	METHODS AND MATE	ERIAL FOR CONTAINMENT	AND CLEANING UP:	
	closed container.		dust, earth, sand, vermiculite, diatomace	eous earth, etc). Keep the remains in a
6.4	REFERENCE TO OTH		- 4	
	For information on safe h For exposure controls an	nd personal protection measures,	, see section 8.	
		w the recommendations in section	on 13.	
SECTION	I 7: HANDLING AND STO			
7.1	PRECAUTIONS FOR			
		legislation on health and safety a	at work.	
	- General recommenda	e or escape.Keep the container t	tightly closed	
		r the prevention of fire and ex		
	The product is not liable environment in which it is for use in potentially expl	to ignite, deflagrate or explode, a s, so it is not included in the scop	and does not sustain the combustion rea oe of Directive 2014/34/EU concerning e	action by oxygen from air in the quipment and protective systems intended
				xposure controls and personal protection
	measures, see section 8		·	
		r the prevention of environme		
		-	ase of accidental spillage, follow the inst	ructions indicated in section 6.
7.2	Forbid the entry to unaut with sunlight. In order to information, see section	avoid leakages, the containers, a		s of heat. If possible, avoid direct contact I placed in a vertical position. For more
	- Class of store: According to current legis	slation		
	- Maximum storage pe			
	12 Months	<u></u>		
	- Temperature interval:	<u>.</u>		
	min:5 °C, max:40 °C (ree	,		
	- Incompatible material			
	Keep away from oxidizing	g agents, acids, alkalis.		
	<ul> <li><u>Type of packaging:</u></li> <li>According to current legis</li> </ul>	elation		
		o III): Directive 2012/18/EU:		
	Not applicable (product f			
7.3	SPECIFIC END USE(S			
	· · · · · · · · · · · · · · · · · · ·		part from that already indicated are not a	available.

	A DATA SHEET (RE nce with Regulation (EC) I	ACH) No. 1907/2006 and Regulation	n (EU) No. 2020/87	8			(	Page 4/12 Language:EN
K	<b>isaval</b>	VAMAR LISO (CE) Code : 4450						
/ersion	: 15 Revi	sion: 02/01/2023	Ρ	Previous revis	ion: 29/04/2020	1	Date of print	ing: 02/01/2023
ECTION	8: EXPOSURE CONTR	OLS/PERSONAL PROTEC	TION					
8.1	CONTROL PARAME	TERS:						
	exposure to chemical ar determination of danger - OCCUPATIONAL EX Not established - BIOLOGICAL LIMIT Not established - DERIVED NO-EFFE Derived no-effect level ( included in REACH. DN recommended by a part	<u>XPOSURE LIMIT VALUE</u> VALUES:	nce should be also <u>S (WEL)</u> e that is considere occupational expo ent regulatory ager	o made to n d safe, deri osure limit (	ational guidance ved from toxicity OEL) for the sai	e documents t / data accordi ne chemical.	for methods for t ing to specific gu OEL values may	idances come
ł	- DERIVED NO-EFFECT L	, ,	DNEL Inhalation		DNEL Cutaneou	S	DNEL Oral	
	Systemic effects, acute an	,	mg/m3		mg/kg bw/d		mg/kg bw/d	
	1,2-benzisothiazol-3(2H)-o		s/r (a)	6,81 (c)	s/r (a)	0,966 (c)	- (a)	– (c)
	Reaction mass of 5-chloro	-2-methyl-2H-isothiazolin-3- methyl-2H-isothiazol-3-one	- (a)	- (c)	- (a)	- (c)	- (a)	- (c)
Ī	- DERIVED NO-EFFECT L effects, acute and chronic:	EVEL, WORKERS:- Local	DNEL Inhalation mg/m3		DNEL Cutaneou mg/cm2	<u>S</u>	DNEL Eyes mg/cm2	
	1,2-benzisothiazol-3(2H)-o	ne	s/r (a)	s/r (c)	a/r <b>(a)</b>	a/r (c)	m/r (a)	- (c)
		-2-methyl-2H-isothiazolin-3- methyl-2H-isothiazol-3-one	- (a)	- (c)	- (a)	- (c)	- (a)	- (c)

one [EC 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)				
- DERIVED NO-EFFECT LEVEL, GENERAL POPULATION:- Systemic effects, acute and chronic:	DNEL Inhalation mg/m3		DNEL Cutaneous mg/kg bw/d	DNEL Eyes mg/kg bw/d
1,2-benzisothiazol-3(2H)-one	s/r (a)	1,2 (c)	s/r (a) 0,345 (C)	2 (a) s/r (c)
Reaction mass of 5-chloro-2-methyl-2H-isothiazolin-3- one [EC 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)	- (a)	- (c)	- (a) - (c)	- (a) – (c)
- LOCAL EFFECTS, ACUTE AND CHRONIC:- Local effects, acute and chronic:	DNEL Inhalation mg/m3		DNEL Cutaneous mg/cm2	DNEL Eyes mg/cm2
1,2-benzisothiazol-3(2H)-one	s/r (a)	s/r (C)	a/r (a) a/r (C)	m/r (a) - (c)
Reaction mass of 5-chloro-2-methyl-2H-isothiazolin-3- one [EC 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)	- (a)	- (c)	- (a) - (c)	- (a) – (c)

(a) - Acute, short-term exposure, (c) - Chronic, long-term or repeated exposure.
 (-) - DNEL not available (without data of registration REACH).
 s/r - DNEL not derived (not identified hazard).

m/r - DNEL not derived (medium hazard).

a/r - DNEL not derived (high hazard).

## - PREDICTED NO-EFFECT CONCENTRATION (PNEC):

PNEC Fresh water	PNEC Marine	PNEC Intermittent
mg/l	mg/l	mg/l
0.00403	0.000403	0.0011
-	-	-
PNEC STP	PNEC Sediments	PNEC Sediments
mg/l	mg/kg dw/d	mg/kg dw/d
1.03	0.0499	0.00499
-	-	-
PNEC Air	PNEC Soil	PNEC Oral
mg/m3	mg/kg dw/d	mg/kg dw/d
s/r	3	n/b
	PNEC Fresh water mg/l 0.00403 - PNEC STP mg/l 1.03 - PNEC Air mg/m3	PNEC Fresh water mg/l         PNEC Marine mg/l           0.00403         0.000403           -         -           PNEC STP mg/l         PNEC Sediments mg/kg dw/d           1.03         0.0499           -         -           PNEC Air mg/m3         PNEC Soil mg/kg dw/d

SAFETY DATA SHEET (REACH) In accordance with Regulation (EC) No. 1907/2006 and Regulation (EU) No. 2020/878

k isav	al	VAMAR LISO (CE) Code : 4450						
ion: 15	Revisi	on: 02/01/2023	Previous revision	on: 29/04/2020		Date of printing: 02/01/2023		
isothiazolin-3- methyl-2H-isc (3:1) (-) - PNEC no n/b - PNEC no	one [EC 2 hthiazol-3-c t available ot derived	oro-2-methyl-2H- 47-500-7] and 2- one [EC 220-239-6] (without data of registration (not bioaccumulative pote			-	-		
s/r - PNEC no	•	not identified hazard).						
ENGINEERIN	f respirator	Provide by the u <del>y system:</del>	adequate ventilation.Whe ise of local exhaust ventil					
- Protection of It is recommen	f eyes and ded to insta f hands an ded to insta	<u>face:</u> Ill water taps or sources with <u>d skin:</u> Ill water taps or sources with	clean water close to the wo	orking area.Barr	ier creams may	/ help to protect the		
exposed areas OCCUPATIO As a general m with the corres	of the skin. NAL EXPO easure on ponding ma of the PPE	Barrier creams should not b <u>SURE CONTROLS: REC</u> prevention and safety in the arking. For more information , protection class, marking, c	e applied once exposure ha <u>BULATION (EU) NO. 2010</u> work place, we recommend on personal protective equ	is occurred. <u>6/425:</u> the use of a ba ipment (storage	isic personal pr , use, cleaning	otection equipment (PPE), , maintenance, type and		
Mask:		No, unless ventilation is	insufficient.					
Safety goggle	es:		d to protect against liquid d disinfect at regular inter					
Face shield:								
Gloves:		expected, gloves of pro min.When short contact should be used, with a l material should be in ac example, temperature), chemicals is clearly low circumstances and pose taken into account.Use	the proper technique of re t of the product with the s	hould be used, cted, use glove n.The breakthi ded period of u eriod of use of andard EN374 specifications p emoving glove	with a breakt with a prote rough time of use.There are a protective g Due to the w provided by the s (without touc	hrough time of >240 ction level 2 or higher the selected glove several factors (for loves resistant against ide variety of e glove supplier should be		
Boots:		No.						
Apron:		No.						
Clothing:		No.						
ENVIRONME Avoid any spills - Spills on the Prevent contar - Spills in wat Do not allow to -Water Ma This product do 2000/60/EC~20 - Emissions to Because of vol VOC (product It is applicable AND VARNISH	(the produc <u>NTAL EXF</u> age in the e <u>soil:</u> nination of s <u>er:</u> o escape in: <u>nagement</u> oes not con 013/39/EU. <u>o the atmos</u> atility, emis: <u>ready for</u> the Directiv UES (define)	to drains, sewers or water co <u>Act:</u> tain any substance included <u>sphere:</u> sions to the atmosphere whi	se into the atmosphere. burses. in the list of priority substan le handling and use may res ion of emissions of volatile o C, Annex I.1): Emission subo	sult. Avoid any r compounds due category c) Coa	elease into the to the use of o ting for exterior	atmosphere. rganic solvents: PAINTS r walls of mineral substrate,		

AFETY DATA S	HEET (RE gulation (EC) N	ACH) No. 1907/2006 and Regulation (	EU) No. 2020/878	Page 6/12 (Language:EN
	Val	VAMAR LISO (CE)		
	pinturas	Code : 4450		
ersion: 15	Revi	sion: 02/01/2023	Previous revision: 29/04/2020	Date of printing: 02/01/2023
limitation of	of emissions o DC (supply): 0	f volatile compounds due to th	e use of organic solvents in certain activities and in c (expressed as carbon), Molecular weight (averag	nstallations:Solvents: 0,83 %
ECTION 9: PHYSIC	AL AND CHE	EMICAL PROPERTIES		
9.1 INFORM	ATION ON B	ASIC PHYSICAL AND CHE	EMICAL PROPERTIES:	
Appearar				
Physical s	ate:		Liquid	
Colour:			Grey	
Odour:			Characteristic	
Odour three	shold:		Not available (mixture).	
Change of	<u>f state</u>			
Melting po	int:		Not available (mixture).	
Initial boili	ng point:		> 100* °C at 760 mmHg	
- Flamma			C C	
Flash poin			Not flammable	
		y or explosive limits:	Not available	
	n temperature		Not applicable (do not sustain comb	oustion)
Stability	in tomporatare			
	ition tempera	turo	825,00* °C	
	ation tempera	luie.	020,00 C	
<u>pH-value</u>			9 at 2000	
pH:			8 at 20°C	
- Viscosi	•			
Dynamic v	,		130 Poise at 20°C	
Kinematic			2631,88* mm2/s at 40ºC	
<u>- Solubili</u>				
Solubility i			Inmiscible	
Liposolubi	ity:		Not applicable (inorganic product).	
	pefficient: n-oo	ctanol/water:	Not applicable (mixture).	
<u>- Volatilit</u> Vapour pr			17,535* mmHg at 20ºC	

17,535\* mmHg at 20°C 12,113\* kPa at 50°C Not available (lack of data).

1,693\* at 20/4ºC < 1 (lighter than air).

Not applicable.

Relative water

1h. 60°C

\*Estimated values based on the substances composing the mixture.
9.2
OTHER INFORMATION:
Information regarding physical hazard classes
No additional information available.
Other security features:
VOC (supply):
0,2 % Weight
VOC (supply):
3,4 g/l
Nonvolatile:
67,12 \* % Weight

Vapour pressure: Evaporation rate:

Relative vapour density:

Particle characteristics

- Explosive properties:

- Oxidizing properties:

Not classified as oxidizing product.

Density Relative density:

Particle size:

Not available.

The values indicated do not always coincide with product specifications. The data for the product specifications can be found in the corresponding technical data sheet. For additional information concerning physical and chemical properties related to safety and environment, see sections 7 and 12.

	_				
	aval	VAMAR LISO (CE) Code : 4450			
ersion: 15	Revi	ision: 02/01/2023	Previous revision	on: 29/04/2020	Date of printing: 02/01/20
ECTION 10: ST	ABILITY AND RE	ACTIVITY			
0.1 <u>REAC</u>	TIVITY:				
- Corr	osivity to metals	<u>s:</u>			
It is not	corrosive to met	tals.			
	phorical proper	<u>ties:</u>			
	pyrophoric.				
	ICAL STABILIT				
		nded storage and handling			
		ZARDOUS REACTIONS			
		ction with oxidizing agents	, acids, alkalis.		
	ITIONS TO AV	<u>OID:</u>			
- Heat					
	way from heat.				
- Ligh					
	ble, avoid direct	contact with sunlight.			
<u>- Air:</u>		4 - d b 4 in b 4			
- Pres		ted by exposure to air, but	should not be left the containers	s open.	
Not rele					
- Sho					
		itive to shocks, but as a re-	commendation of a general natu	re should be avoided bumps	and rough handling to ave
			in the product is handled in large		
	<b>IPATIBLE MAT</b>				
		ng agents, acids, alkalis.			
		MPOSITION PRODUCT	<u>S:</u>		
			dous products may be produced	: nitrogen oxides, hydrochlori	c acid, sulfur oxides,
haloge	nated compound	S.			
CTION 11: TO	XICOLOGICAL II	NFORMATION			
carried	l out by using th	ne conventional calculati	paration is available. The toxic on method of the Regulation DEFINED IN REGULATION (	(EU) No. 1272/2008~2021/	/849 (CLP).
ACUT	<u>E TOXICITY:</u>				
	E TOXICITY: and lethal conce	entrations	DL50 (OECD401)		) CL50 (OECD4
Dose a for indi	and lethal conce vidual ingredier	nts:	DL50 (OECD401) mg/kg bw Ora	DL50 (OECD402 mg/kg bw Cutaneous	ś mg/m3·4ĥ Inhalat
Dose a for indi 1,2-bei	nd lethal conce vidual ingredier nzisothiazol-3(2	nts: ?H)-one	DL50 (OECD401) mg/kg bw Ora 490 Rat	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra	s mg/m3·4h Inhalat t
Dose a for indi 1,2-bei Reactio	nd lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch	nts: 2H)-one nloro-2-methyl-2H-	DL50 (OECD401) mg/kg bw Ora	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra	s mg/m3·4h Inhalat t
Dose a for indi 1,2-bei Reactio isothia:	nd lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC	nts: 2H)-one nloro-2-methyl-2H- ; 247-500-7] and 2-	DL50 (OECD401) mg/kg bw Ora 490 Rat	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra	s mg/m3·4h Inhalat t
Dose a for indi 1,2-bei Reactio isothia methyl	nd lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC	nts: 2H)-one nloro-2-methyl-2H-	DL50 (OECD401) mg/kg bw Ora 490 Rat	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra	s mg/m3·4h Inhalat t
Dose a for indi 1,2-bei Reactio isothia: methyl (3:1)	nd lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3	nts: 2H)-one nloro-2-methyl-2H- ; 247-500-7] and 2- 3-one [EC 220-239-6]	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra	s mg/m3·4h Inhalat t > 1230
Dose a for indi 1,2-bei Reactio isothia: methyl (3:1) Estima	nd lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox	nts: 2H)-one 1loro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] xicity (ATE)	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra	s mg/m3·4h Inhalat t > 1230
Dose a for indi 1,2-bei Reactio isothia: methyl (3:1) Estima for indi	nd lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier	nts: 2H)-one nloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] cicity (ATE) nts:	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 74,9 Rat MTE mg/kg bw Ora	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra 140 Ra MTE mg/kg bw Cutaneous	s mg/m3·4h Inhalat t > 1230
Dose a for indi 1,2-bei Reactio isothia: methyl (3:1) Estima for indi 1,2-bei	nd lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier nzisothiazol-3(2	nts: 2H)-one nloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] cicity (ATE) nts: 2H)-one	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 74,9 Rat MTE mg/kg bw Ora 490	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra 140 Ra Mg/kg bw Cutaneous	s mg/m3·4h Inhalat t t > 1230 s mg/m3·4h Inhalat
Dose a for indi 1,2-ber Reaction isothia: methyl (3:1) Estima for indi 1,2-ber Reaction	nd lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier nzisothiazol-3(2 on mass of 5-ch	nts: 2H)-one hloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] kicity (ATE) nts: 2H)-one hloro-2-methyl-2H-	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 74,9 Rat MTE mg/kg bw Ora	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra 140 Ra Mg/kg bw Cutaneous	s mg/m3·4h Inhalat t t > 1230 s mg/m3·4h Inhalat
Dose a for indi 1,2-ber Reaction isothia: methyl (3:1) Estima for indi 1,2-ber Reaction isothia:	nd lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC	nts: 2H)-one hloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] cicity (ATE) nts: 2H)-one hloro-2-methyl-2H- 247-500-7] and 2-	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 74,9 Rat MTE mg/kg bw Ora 490	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra 140 Ra Mg/kg bw Cutaneous	s mg/m3·4h Inhalat t t > 1230 s mg/m3·4h Inhalat
Dose a for indi 1,2-ber Reaction isothia: methyl (3:1) Estima for indi 1,2-ber Reaction isothia: methyl	nd lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC	nts: 2H)-one hloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] kicity (ATE) nts: 2H)-one hloro-2-methyl-2H-	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 74,9 Rat MTE mg/kg bw Ora 490	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra 140 Ra Mg/kg bw Cutaneous	s mg/m3·4h Inhalat t t > 1230 l s mg/m3·4h Inhalat
Dose a for indi 1,2-bei Reaction isothia: methyl (3:1) Estima for indi 1,2-bei Reaction isothia: methyl (3:1)	nd lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3	nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] cticity (ATE) nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6]	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat ATE mg/kg bw Ora 490 74,9	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra Mg/kg bw Cutaneous 140	s mg/m3·4h Inhalat t > 1230 l s mg/m3·4h Inhalat
Dose a for indi 1,2-bei Reaction isothia: methyl (3:1) Estima for indi 1,2-bei Reaction isothia: methyl (3:1) (*) - Po	Ind lethal concernation of the stimates of acute to xvidual ingrediernation of the stimates of 5-ch color of the stimates of acute to xvidual ingrediernation of 5-ch color of 5-ch colo	nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] kicity (ATE) nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] acute toxicity correspondin	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat ATE mg/kg bw Ora 490 74,9 g to the classification category (s	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra Mg/kg bw Cutaneous 140 Seee GHS/CLP Table 3.1.2). Th	s mg/m3·4h Inhalat t > 1230 I s mg/m3·4h Inhalat o *>
Dose a for indi 1,2-bei Reaction isothia: methyl (3:1) Estima for indi 1,2-bei Reaction isothia: methyl (3:1) (*) - Poo be used (-) - The	ind lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 int estimates of a d in the calculatic e components the	nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] cicity (ATE) nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] acute toxicity correspondin on of the ATE for classification	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat ATE mg/kg bw Ora 490 74,9	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra Mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). The mponents and do not represe	s mg/m3·4h Inhalat t t > 1230 l s mg/m3·4h Inhalat s mg/m3·4h Inhalat > *>
Dose a for indi 1,2-ber Reaction isothia: methyl (3:1) Estima for indi 1,2-ber Reaction isothia: methyl (3:1) (*) - Po be user	ind lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 int estimates of a d in the calculatic e components the	nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] cicity (ATE) nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] acute toxicity correspondin on of the ATE for classification	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 74,9 Rat MTE mg/kg bw Ora 490 74,9 74,9 g to the classification category (stion of a mixture based on its co	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra Mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). The mponents and do not represe	s mg/m3·4h Inhalat t t > 1230 l s mg/m3·4h Inhalat s mg/m3·4h Inhalat > *>
Dose a for indi 1,2-bei Reactive isothia: methyl (3:1) Estima for indi 1,2-bei Reactive isothia: methyl (3:1) (*) - Po be used (-) - Th are ign	Ind lethal concernation of the second state of a cuttor to the second state of a cuttor of	nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] kicity (ATE) nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] acute toxicity correspondin on of the ATE for classification at are assumed to have no	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat ATE mg/kg bw Ora 490 74,9 g to the classification category (stion of a mixture based on its co o acute toxicity at the upper three	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). The mponents and do not represe shold of category 4 for the cor	s mg/m3·4h Inhalat t > 1230 l > 1230 l > 1230 l > mg/m3·4h Inhalat > *> hese values are designed ent test results. rresponding exposure rout
Dose a for indi 1,2-bei Reactive isothia: methyl (3:1) Estima for indi 1,2-bei Reactive isothia: methyl (3:1) (*) - Po be used (-) - Th are ign	ind lethal conce vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 int estimates of a d in the calculatic e components the	nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] kicity (ATE) nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] acute toxicity correspondin on of the ATE for classification at are assumed to have no	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 74,9 Rat mg/kg bw Ora 490 74,9 g to the classification category (stion of a mixture based on its co b acute toxicity at the upper three NOAEL Ora	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). Th mponents and do not represe shold of category 4 for the cor NOAEL Cutaneous	s mg/m3·4h Inhalat t > 1230 l > 1230 l > 1230 l > mg/m3·4h Inhalat > *> hese values are designed ent test results. rresponding exposure rout
Dose a for indi 1,2-bei Reactive isothia: methyl (3:1) Estima for indi 1,2-bei Reactive isothia: methyl (3:1) (*) - Po be usei (-) - Th are ign	Ind lethal concern vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 int estimates of a d in the calculatic e components the ored.	nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] kicity (ATE) nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] acute toxicity correspondin on of the ATE for classificat at are assumed to have no e effect level	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 74,9 Rat ATE mg/kg bw Ora 490 74,9 g to the classification category (st tion of a mixture based on its co o acute toxicity at the upper three NOAEL Ora mg/kg bw/d	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). The mponents and do not represe shold of category 4 for the cor NOAEL Cutaneous mg/kg bw/d	s mg/m3·4h Inhalat t > 1230 l > 1230 l > 1230 l > mg/m3·4h Inhalat > *> hese values are designed ent test results. rresponding exposure rout
Dose a for indi 1,2-bei Reactive isothia: methyl (3:1) Estima for indi 1,2-bei Reactive isothia: methyl (3:1) (*) - Po be usei (-) - Th are ign	Ind lethal concernation of the second state of a cute to xvidual ingrediernation of 5-ch color of 5-ch color of 5-ch color of 5-ch color of a cute to xvidual ingrediernation of 5-ch color of 5-ch co	nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] kicity (ATE) nts: 2H)-one nloro-2-methyl-2H- 5 247-500-7] and 2- 3-one [EC 220-239-6] acute toxicity correspondin on of the ATE for classificat at are assumed to have no e effect level	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 74,9 Rat mg/kg bw Ora 490 74,9 g to the classification category (stion of a mixture based on its co b acute toxicity at the upper three NOAEL Ora	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). The mponents and do not represe shold of category 4 for the cor NOAEL Cutaneous mg/kg bw/d	s mg/m3·4h Inhalat t > 1230 l > 1230 l > 1230 l > mg/m3·4h Inhalat > *> hese values are designed ent test results. rresponding exposure rout
Dose a for indi 1,2-ber Reaction isothia: methyl (3:1) Estima for indi 1,2-ber Reaction isothia: methyl (3:1) (*) - Poo be user (-) - Th are ign - No ot 1,2-ber - Lowe Not ava	Ind lethal concernation of the second	nts: 2H)-one nloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] xicity (ATE) nts: 2H)-one nloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] acute toxicity correspondin on of the ATE for classificat at are assumed to have no e effect level 2H)-one verse effect level	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 74,9 Rat ATE mg/kg bw Ora 490 74,9 g to the classification category (st tion of a mixture based on its co o acute toxicity at the upper thres NOAEL Ora mg/kg bw/d 69 Rat	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). Th mponents and do not represe shold of category 4 for the cor NOAEL Cutaneous mg/kg bw/d	s mg/m3·4h Inhalat t > 1230 l > 1230 l > 1230 l > mg/m3·4h Inhalat > *> hese values are designed ent test results. rresponding exposure rout
Dose a for indi 1,2-ber Reaction isothia: methyl (3:1) Estima for indi 1,2-ber Reaction isothia: methyl (3:1) (*) - Poo be user (-) - Th are ign - No ot 1,2-ber - Lowe Not ava	Ind lethal concernation of the second	nts: 2H)-one nloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] xicity (ATE) nts: 2H)-one nloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] acute toxicity correspondin on of the ATE for classificat at are assumed to have no e effect level 2H)-one verse effect level	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 74,9 Rat ATE mg/kg bw Ora 490 74,9 g to the classification category (st tion of a mixture based on its co o acute toxicity at the upper three NOAEL Ora mg/kg bw/d	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). Th mponents and do not represe shold of category 4 for the cor NOAEL Cutaneous mg/kg bw/d	s mg/m3·4h Inhalat t > 1230 f > 1230 f > 1230 f > mg/m3·4h Inhalat > *> hese values are designed ent test results. rresponding exposure rout
Dose a for indi 1,2-bei Reactive isothia: methyl (3:1) Estima for indi 1,2-bei Reactive isothia: methyl (3:1) (*) - Po be use (-) - Th are ign - No of 1,2-bei - Lowe Not ava INFOF	Ind lethal concernation of the second	nts: 2H)-one nloro-2-methyl-2H- 3-one [EC 220-239-6] dicity (ATE) nts: 2H)-one nloro-2-methyl-2H- 3-one [EC 220-239-6] acute toxicity correspondin on of the ATE for classificat at are assumed to have no e effect level 2H)-one verse effect level <u>IKELY ROUTES OF EX</u> Acute toxicity	DL50 (OECD401) mg/kg bw Ora 490 Rai 74,9 Rai 74,9 Rai 9 Content of the second second 74,9 74,9 74,9 74,9 74,9 74,9 74,9 74,9	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). Th mponents and do not represe shold of category 4 for the cor NOAEL Cutaneous mg/kg bw/d	s mg/m3·4h Inhalat t t > 1230 f > 1230 f > 1230 f s mg/m3·4h Inhalat c A mg/m3·4h Inhalat *> hese values are designed ent test results. rresponding exposure rout s NOAEC Inhalat mg/
Dose a for indi 1,2-bei Reaction isothia: methyl (3:1) Estima for indi 1,2-bei Reaction isothia: methyl (3:1) (*) - Po be use (-) - Thi are ign - No of 1,2-bei Reaction isothia: methyl (3:1) (*) - Po be use (-) - Thi are ign - No of 1,2-bei Routes Not ava INFOF	Ind lethal concern vidual ingredier inzisothiazol-3(2 con mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier inzisothiazol-3(2 con mass of 5-ch zolin-3-one [EC -2H-isothiazol-3(2 con mass of 5-ch zolin-3-one [EC -2H-isothiazol-3(2 con mass of 5-ch zolin-3-one [EC -2H-isothiazol-3(2 con mass of 3-ch zolin-3-one [EC -3-ch zolin-3-one [EC -3-	nts: 2H)-one nloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] dicity (ATE) nts: 2H)-one nloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] acute toxicity correspondin on of the ATE for classificar at are assumed to have no e effect level 2H)-one verse effect level IKELY ROUTES OF EX	DL50 (OECD401) mg/kg bw Ora 490 Rai 74,9 Rai 74,9 Rai 9 Content of the second second 74,9 74,9 74,9 74,9 74,9 74,9 74,9 74,9	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). Th mponents and do not represe shold of category 4 for the cor NOAEL Cutaneous mg/kg bw/d Main effects, acute and/or of Not classified as a product	s mg/m3·4h Inhalat t > 1230 f > 1230 f > 1230 f > 1230 f > mg/m3·4h Inhalat o *> hese values are designed ent test results. rresponding exposure rout s NOAEC Inhalat mg/
Dose a for indi 1,2-bei Reaction isothia: methyl (3:1) Estima for indi 1,2-bei Reaction isothia: methyl (3:1) (*) - Po be use (-) - Thi are ign - No of 1,2-bei Reaction isothia: methyl (3:1) (*) - Po be use (-) - Thi are ign - No of 1,2-bei Routes Not ava INFOF	and lethal concern vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier nzisothiazol-3(2 on mass of 5-ch zolin-3-one [EC -2H-isothiazol-3(2 on mass of s-ch zolin-3-one [EC -2H-isothiazol-3(2 extension adverse nzisothiazol-3(2 extension adverse nzisothiazol-3(2 extension adverse nzisothiazol-3(2 extension adverse nzisothiazol-3(2 extension adverse maint adverse maint adverse maint adverse maint adverse extension adverse maint	nts: 2H)-one nloro-2-methyl-2H- 3-one [EC 220-239-6] dicity (ATE) nts: 2H)-one nloro-2-methyl-2H- 3-one [EC 220-239-6] acute toxicity correspondin on of the ATE for classificat at are assumed to have no e effect level 2H)-one verse effect level <u>IKELY ROUTES OF EX</u> Acute toxicity	DL50 (OECD401) mg/kg bw Ora 490 Rai 74,9 Rai 74,9 Rai 9 Content of the second second 74,9 74,9 74,9 74,9 74,9 74,9 74,9 74,9	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). Th mponents and do not represe shold of category 4 for the cor NOAEL Cutaneous mg/kg bw/d Main effects, acute and/or of Not classified as a product if inhaled (based on availab	s mg/m3·4h Inhalat t > 1230 l > 1230 l > 1230 l > mg/m3·4h Inhalat s mg/m3·4h Inhalat > *> hese values are designed ent test results. rresponding exposure rout s NOAEC Inhalat mg/ delayed Criteria with acute toxicity GHS/C ble data, the 3.1.3.6.
Dose a for indi 1,2-bei Reactive isothia: methyl (3:1) Estima for indi 1,2-bei Reactive isothia: methyl (3:1) (*) - Po be usei (-) - Thi are ign - No of 1,2-bei Mot ava INFOF Routes Inhalat Not classical States of the second Routes	Ind lethal concern vidual ingredier inzisothiazol-3(2 con mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier inzisothiazol-3(2 con mass of 5-ch zolin-3-one [EC -2H-isothiazol-3(2 con mass of 5-ch zolin-3-one [EC -2H-isothiazol-3(2 con mass of 5-ch zolin-3-one [EC -2H-isothiazol-3(2 con mass of 3-ch zolin-3-one [EC -3-ch zolin-3-one [EC -3-	nts: 2H)-one hloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] dicity (ATE) hts: 2H)-one hloro-2-methyl-2H- 247-500-7] and 2- 3-one [EC 220-239-6] acute toxicity correspondin on of the ATE for classification at are assumed to have not e effect level 2H)-one verse effect level IKELY ROUTES OF EX Acute toxicity ATE > 20000	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 74,9 Rat ATE mg/kg bw Ora 490 74,9 g to the classification category ( tion of a mixture based on its co o acute toxicity at the upper three bacute toxicity at the upper three NOAEL Ora mg/kg bw/d 69 Rat	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). Th mponents and do not represe shold of category 4 for the cor NOAEL Cutaneous mg/kg bw/d Main effects, acute and/or of Not classified as a product if inhaled (based on availab classification criteria are no	s mg/m3·4h Inhalat t > 1230 l > 1230 l > 1230 l > 1230 l > mg/m3·4h Inhalat > mg/m3·4h Inhalat > *> hese values are designed ent test results. rresponding exposure rout s NOAEC Inhalat mg/ delayed Criteria with acute toxicity GHS/C ble data, the with acute toxicity GHS/C 3.1.3.6.
Dose a for indi 1,2-ber Reaction isothia: methyl (3:1) Estima for indi 1,2-ber Reaction isothia: methyl (3:1) (*) - Po be user (-) - Th are ign - No of 1,2-ber Not ava INFOF Routes Inhalat Not cla	Ind lethal concern vidual ingredier inzisothiazol-3(2 con mass of 5-ch zolin-3-one [EC -2H-isothiazol-3 tes of acute tox vidual ingredier inzisothiazol-3(2 con mass of 5-ch zolin-3-one [EC -2H-isothiazol-3(2 con mass of 5-ch zolin-3-one [EC -2H-isothiazol-3(2 con mass of 5-ch zolin-3-one [EC -2H-isothiazol-3(2 con mass of 3-ch zolin-3-one [EC -3-ch zolin-3-one [EC -3-	nts: 2H)-one nloro-2-methyl-2H- 3-one [EC 220-239-6] dicity (ATE) nts: 2H)-one nloro-2-methyl-2H- 3-one [EC 220-239-6] acute toxicity correspondin on of the ATE for classificat at are assumed to have no e effect level 2H)-one verse effect level <u>IKELY ROUTES OF EX</u> Acute toxicity	DL50 (OECD401) mg/kg bw Ora 490 Rat 74,9 Rat 74,9 Rat ATE mg/kg bw Ora 490 74,9 g to the classification category ( tion of a mixture based on its co o acute toxicity at the upper three bacute toxicity at the upper three NOAEL Ora mg/kg bw/d 69 Rat	DL50 (OECD402 mg/kg bw Cutaneous > 2000 Ra 140 Ra ATE mg/kg bw Cutaneous 140 see GHS/CLP Table 3.1.2). Th mponents and do not represe shold of category 4 for the cor NOAEL Cutaneous mg/kg bw/d Main effects, acute and/or of Not classified as a product if inhaled (based on availab	s mg/m3·4h Inhalat t > 1230 l > 1230 l > 1230 l > 1230 l > mg/m3·4h Inhalat > mg/m3·4h Inhalat > *> hese values are designed ent test results. rresponding exposure rout s NOAEC Inhalat mg/ delayed Criteria with acute toxicity GHS/C 3.1.3.6. with acute toxicity GHS/C

Revision: 02/01/2023



Version: 15

VAMAR LISO (CE) Code : 4450

Previous revision: 29/04/2020

Date of printing: 02/01/2023

Eyes: Not classified	Not available.	Not classified as a product with acute toxicity by eye contact (lack of data).	GHS/CLP 1.2.5.
Ingestion: Not classified	ATE > 5000 mg/kg bw	Not classified as a product with acute toxicity if swallowed (based on available data, the classification criteria are not met).	GHS/CLP 3.1.3.6.

GHS/CLP 3.1.3.6: Classification of mixtures based on ingredients of the mixture (additivity formula).

## CORROSION / IRRITATION / SENSITISATION :

Danger class	Target organs	Cat.	Main effects, acute and/or delayed	Criteria
- Respiratory corrosion/irritation: Not classified	-	-	Not classified as a product corrosive or irritant by inhalation (based on available data the classification criteria are not met).	GHS/CLP 1.2.6. 3.8.3.4.
- Skin corrosion/irritation: Not classified	-	-	Not classified as a product corrosive or irritant in contact with skin (based on available data, the classification criteria are not met).	GHS/CLP 3.2.3.3.
- Serious eye damage/irritation: Not classified	-	-	Not classified as a product corrosive or irritant in contact with eyes (based on available data, the classification criteria are not met).	GHS/CLP 3.3.3.3.
<ul> <li>Respiratory sensitisation: Not classified</li> </ul>	-	-	Not classified as a product sensitising by inhalation (based on available data, the classification criteria are not met).	GHS/CLP 3.4.3.3.
- Skin sensitisation: Not classified	-	-	Not classified as a product sensitising by skin contact (based on available data, the classification criteria are not met).	GHS/CLP 3.4.3.3.

GHS/CLP 3.2.3.3: Classification of the mixture when data are available for all components or only for some components. GHS/CLP 3.3.3.3: Classification of the mixture when data are available for all components or only for some components. GHS/CLP 3.4.3.3: Classification of the mixture when data are available for all components or only for some components. GHS/CLP 3.8.3.4: Classification of the mixture when data are available for all components or only for some components. GHS/CLP 3.8.3.4: Classification of the mixture when data are available for all components or only for some components.

## - ASPIRATION HAZARD:

Danger class	Target organs	Cat.	Main effects, acute and/or delayed	Criteria
- Aspiration hazard:	-	-	Not classified as a product hazardous by	GHS/CLP
Not classified			aspiration (based on available data, the classification criteria are not met).	3.10.3.3.

GHS/CLP 3.10.3.3: Classification of the mixture when data are available for all components or only for some components.

SPECIFIC TARGET ORGANS TOXICITY (STOT): Single exposure (SE) and/or Repeated exposure (RE): Not classified as a dangerous product for target organs.

GHS/CLP 3.8.3.4: Classification of the mixture when data are available for all components or only for some components.

## **CMR EFFECTS:**

- Carcinogenic effects:

It is not considered as a carcinogenic product.

- Genotoxicity:

It is not considered as a mutagenic product.

- Toxicity for reproduction:

Does not harm fertility.Does not harm the unborn child.

- Effects via lactation:

Not classified as a hazardous product for children breast-fed.

DELAYED AND IMMEDIATE EFFECTS AS WELL AS CHRONIC EFFECTS FROM SHORT AND LONG-TERM EXPOSURE: Routes of exposure

Not available. <u>- Short-term exposure:</u> Not available. <u>- Long-term or repeated exposure:</u> Not available.

INTERACTIVE EFFECTS: Not available.

$\prec$	isa	<b>vdl</b> inturas	VAMAR LISO (CE) Code : 4450				
/ersior	n: 15	Revi	sion: 02/01/2023	Previous revisior	n: 29/04/2020	Date of printing: 02/01/202	
			JT TOXICOCINETIC	<u>S, METABOLISM AND DISTRIBU</u>	JTION:		
	- Dermal a Not available						
	- Basic tox						
	Not available		•				
	ADDITION Not available		<u>MATION:</u>				
11.2			THER HAZARDS:				
	Endocrine						
			Ibstances with endocrination of the standard state with the state with t	ne disrupting properties identified or	under evaluation in a concent	ration of less than 0.1% b	
	Other infor			<b>.</b> ).			
	No additiona		n available.				
ECTION	N 12: ECOLO	GICAL INFC	RMATION				
12.1	TOXICITY:						
				ne preparation as such is availabl conventional calculation method o			
	(CLP).	been cam	ied out by using the c			21212000~2021/049	
	<u> </u>	city in aqua	tic environment	CL50 (OECD 203)	CE50 (OECD 202)	CE50 (OECD 20	
	for individua	•		mg/l·96hours	`mg/l·48hours´	mg/l·72hou	
	1,2-benzisc			2.2 - Fishes	2.9 - Daphniae	0.11 - Alga	
			loro-2-methyl-2H- 247-500-7] and 2-	0.19 - Fishes	0.16 - Daphniae	0.037 - Alga	
			-one [EC 220-239-6]				
	(3:1)						
	No observ	ed effect o	oncentration	NOEC (OECD 210)	NOEC (OECD 211)	NOEC (OECD 20	
				mg/l · 28 days	mg/l · 21 days	mg/l · 72 hou	
	1,2-benzisc	•			0.011 Dophpico	0.04 - Alga	
			loro-2-methyl-2H- 247-500-7] and 2-	0.02 - Fishes	0.011 - Daphniae	0.004 - Alga	
	methyl-2H-isothiazol-3-one [EC 220-239-6]						
	(3:1)						
	- Lowest observed effect concentration						
	Not available						
			QUATIC TOXICITY:				
	Aquatic toxi	city	Cat.	Main hazards to the aquatic environ	iment	Criteria	
	- Acute aqu	atic toxicity:		ot classified as a hazardous product with acute toxicity to aquatic life GHS/		ic life GHS/CLP	
	Not classifie	ed		(based on available data, the classi		4.1.3.5.5.3.	
				Not classified as a dangerous produ with long lasting effects (based on a			
				are not met).		n chiena 4.1.3.3.3.4.	
	CLP 4.1.3.5.5.3: Classification of a mixture for acute hazards, based on summation of classified components. CLP 4.1.3.5.5.4: Classification of a mixture for chronic (long term) hazards, based on summation of classified components.						
12.2			DEGRADABILITY:				
	- Biodegradability: Not available.						
	Aerobic biodegradation			COD	%DBO/DQO	Biodegradabilida	
	for individual ingredients			mgO2/g	5 days 14 days 28 days	5	
	1,2-benzisothiazol-3(2H)-one					Not eas	
	Reaction mass of 5-chloro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2-				55	Not eas	
			-one [EC 220-239-6]				
	(3:1)						
			ata correspond to an a	verage of data from various bibliogra	phic sources.		
	- Hydrolysis						
	Not available						
	- <u>Photodegradability:</u> Not available.						
	Not available	Э.					
12.3			POTENTIAL:				

SAFETY DATA		ACH) No. 1907/2006 and Regulation	(EU) No. 2020/878	Page 10/12 (Language:EN)
<b>R</b> isa	aval pinturas	VAMAR LISO (CE) Code : 4450		
Version: 15	Revi	sion: 02/01/2023	Previous revision: 29/04/2020	Date of printing: 02/01/2023

	Bioaccumulation for individual ingredients	logPow	BCF L/kg	Potentia
	1,2-benzisothiazol-3(2H)-one	0.7	6.62 (calculated)	Unlikely, lov
	Reaction mass of 5-chloro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)	0.75	3.2 (calculated)	Unlikely, lov
12.4	MOBILITY IN SOIL: Not available			
	Mobility for individual ingredients	log Poc	Constant of Henry Pa·m3/mol 20°C	Potentia
	1,2-benzisothiazol-3(2H)-one Reaction mass of 5-chloro-2-methyl-2H- isothiazolin-3-one [EC 247-500-7] and 2- methyl-2H-isothiazol-3-one [EC 220-239-6] (3:1)	0,97 0,45		Unlikely, lov Unlikely, lov
12.5	RESULTS OF PBT AND VPVB ASSESMENT:	• • • • •	o. 1907/2006: <u>)</u>	
	Does not contain substances that fulfil the PBT/vPv	/B criteria.		
12.6	ENDOCRINE DISRUPTING PROPERTIES: This product contains substances with endocrine d weight:2,2-dibromo-2-cyanoacetamide (DBNPA).	isrupting properties identified or uno	der evaluation in a concentration	of less than 0.1% by
12.7	OTHER ADVERSE EFFECTS: - Ozone depletion potential: Not available. - Photochemical ozone creation potential: Not available. Forth global warming potential:			
	- Earth global warming potential: Not available.			
ECTIO	N 13: DISPOSAL CONSIDERATIONS			
13.1	WASTE TREATMENT METHODS: Directive 20	008/98/EC~Regulation (EU) no.	1357/2014:	
	Take all necessary measures to prevent the product Do not discharge into drains or the environment, di accordance with current local and national regulated Disposal of empty containers:Directive 94/62/E Emptied containers and packaging should be dispo- packaging as hazardous waste will depend on the classification, in accordance with Chapter 15 01 of contaminated containers and packaging, adopt the Procedures for neutralising or destroying the p Authorised landfill in accordance with local regulati	spose at an authorised waste collect ons. For exposure controls and pers <u>C~2015/720/EU, Decision 2000</u> , used in accordance with currently lo degree of empting of the same, bein Decision 2000/532/EC, and forward same measures as for the product roduct:	ction point. Waste should be hand sonal protection measures, see s / <u>532/EC~2014/955/EU:</u> cal and national regulations. The ng the holder of the residue respo ling to the appropriate final destin	dled and disposed in ection 8. classification of onsible for their
ECTIO	N 14: TRANSPORT INFORMATION			
14.1	UN NUMBER OR ID NUMBER:			
14.2	Not applicable           UN PROPER SHIPPING NAME:           Not applicable			
14.2	Not applicable         UN PROPER SHIPPING NAME:         Not applicable         TRANSPORT HAZARD CLASS(ES):         Transport by road (ADR 2021) and         Transport by rail (RID 2021):         No reglamented         Transport by sea (IMDG 39-18):         No reglamented         Transport by air (ICAO/IATA 2021):         No reglamented         Transport by air (ICAO/IATA 2021):         No reglamented         Transport by air (ICAO/IATA 2021):         No reglamented         Transport by inland waterways (ADN):			
14.3	Not applicable         UN PROPER SHIPPING NAME:         Not applicable         TRANSPORT HAZARD CLASS(ES):         Transport by road (ADR 2021) and         Transport by rail (RID 2021):         No reglamented         Transport by sea (IMDG 39-18):         No reglamented         Transport by air (ICAO/IATA 2021):         No reglamented         Transport by inland waterways (ADN):         No reglamented         PACKING GROUP:			
14.3	Not applicable         UN PROPER SHIPPING NAME:         Not applicable         TRANSPORT HAZARD CLASS(ES):         Transport by road (ADR 2021) and         Transport by rail (RID 2021):         No reglamented         Transport by sea (IMDG 39-18):         No reglamented         Transport by air (ICAO/IATA 2021):         No reglamented         Transport by inland waterways (ADN):         No reglamented         PACKING GROUP:         No reglamented			
14.3	Not applicable         UN PROPER SHIPPING NAME:         Not applicable         TRANSPORT HAZARD CLASS(ES):         Transport by road (ADR 2021) and         Transport by rail (RID 2021):         No reglamented         Transport by sea (IMDG 39-18):         No reglamented         Transport by air (ICAO/IATA 2021):         No reglamented         Transport by inland waterways (ADN):         No reglamented         PACKING GROUP:	environment).		
	Not applicable         UN PROPER SHIPPING NAME:         Not applicable         TRANSPORT HAZARD CLASS(ES):         Transport by road (ADR 2021) and         Transport by rail (RID 2021):         No reglamented         Transport by sea (IMDG 39-18):         No reglamented         Transport by air (ICAO/IATA 2021):         No reglamented         Transport by inland waterways (ADN):         No reglamented         PACKING GROUP:         No reglamented         ENVIRONMENTAL HAZARDS:         Not applicable (not classified as hazardous for the         SPECIAL PRECAUTIONS FOR USER:         Ensure that persons transporting the product know		pill. Always transport in closed co	ntainers that are
14.3 14.4 14.5	Not applicable         UN PROPER SHIPPING NAME:         Not applicable         TRANSPORT HAZARD CLASS(ES):         Transport by road (ADR 2021) and         Transport by rail (RID 2021):         No reglamented         Transport by sea (IMDG 39-18):         No reglamented         Transport by air (ICAO/IATA 2021):         No reglamented         Transport by inland waterways (ADN):         No reglamented         PACKING GROUP:         No reglamented         ENVIRONMENTAL HAZARDS:         Not applicable (not classified as hazardous for the         SPECIAL PRECAUTIONS FOR USER:	what to do in case of accident or sp	pill. Always transport in closed co	ntainers that are

Not applicable.

Code : 4450

Revision: 02/01/2023

Version: 15

Previous revision: 29/04/2020

Date of printing: 02/01/2023

Page 11/12

SECTION	15: REGULATORY INFORMATION	
15.1	SAFETY, HEALTH AND ENVIRONMENTAL REGULATIONS/LEGISLATION SPECIFIC FOR THE SUBSTANCE OR MIXTU	JRE:
	The regulations applicable to this product generally are listed throughout this Safety Data Sheet.	
	Restrictions on manufacture, placing on market and use:	
	See section 1.2	
	Tactile warning of danger:	
	Not applicable (the classification criteria are not met).	
	Child safety protection:	
	Not applicable (the classification criteria are not met).	
	VOC information on the label:	
	Contains VOC max. 3,4 for the product ready for use - The limit value 2004/42/EC-IIA cat. c) Coating for exterior walls of mineral subst	rate,
	water-borne. is VOC max. 40 g/l (2010)	
	OTHER REGULATIONS:	
	Control of the risks inherent in major accidents (Seveso III):	
	See section 7.2	
	Other local legislations:	
17.0	The receiver should verify the possible existence of local regulations applicable to the chemical.	
15.2	CHEMICAL SAFETY ASSESSMENT:	
	A chemical safety assessment has not been carried out for this mixture.	
SECTION	16 : OTHER INFORMATION	
16.1	TEXT OF THE PHRASES AND NOTES REFERENCED IN SECTIONS 2 AND/OR 3:	
	Hazard statements according the Regulation (EU) No. 1272/2008~2021/849 (CLP), Annex III:	
	H301 Toxic if swallowed. H302 Harmful if swallowed. H310 Fatal in contact with skin. H314 Causes severe skin burns and eye damage	
	H315 Causes skin irritation. H317 May cause an allergic skin reaction. H318 Causes serious eye damage. H330 Fatal if inhaled. H400 toxic to aquatic life. H410 Very toxic to aquatic life with long lasting effects. EUH071 Corrosive to the respiratory tract.	Very
	Notes related to the identification, classification and labelling of the substances or mixtures: Note B : Some substances (acids, bases, etc.) are placed on the market in aqueous solutions at various concentrations and, therefore,	
	these solutions require different classification and labelling since the hazards vary at different concentrations. In Part 3 entries with Note	۶R
	have a general designation of the following type: 'nitric acid %'. In this case the supplier must state the percentage concentration of t	
	solution on the label. Unless otherwise stated, it is assumed that the percentage concentration is calculated on a weight/weight basis.	
	EVALUATION OF THE INFORMATION ON THE DANGER OF MIXTURES:	
	See sections 9.1, 11.1 and 12.1.	
	ADVICES ON ANY TRAINING APPROPRIATE FOR WORKERS:	
	It is recommended for all staff that will handle this product to carry out a basic training in occupational risk and prevention, in order to	
	provide understanding and interpretation of Safety Data Sheets and labelling of products as well.	
	MAIN LITERATURE REFERENCES AND SOURCES FOR DATA:	
	· European Chemicals Agency: ECHA, http://echa.europa.eu/	
	· Access to European Union Law, http://eur-lex.europa.eu/	
	<ul> <li>European agreement on the international carriage of dangerous goods by road, (ADR 2021).</li> <li>International Maritime Dangerous Goods Code IMDG including Amendment 39-18 (IMO, 2018).</li> </ul>	
	ABBREVIATIONS AND ACRONYMS:	
	List of abbreviations and acronyms that can be used (but not necessarily used) in this Safety Data Sheet:	
	· REACH: Regulation concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals.	
	· GHS: Globally Harmonized System of Classification and Labelling of Chemicals of the United Nations.	
	<ul> <li>CLP: European regularion on Classificatin, Labelling amd Packaging of substances and chemical mixtures.</li> <li>EINECS: European Inventory of Existing Commercial Chemical Substances.</li> </ul>	
	· ELINCS: European List of Notified Chemical Substances.	
	· CAS: Chemical Abstracts Service (Division of the American Chemical Society).	
	· UVCB: Substances of Unknown or Variable composition, complex reaction products or biological materials.	
	· SVHC: Substances of Very High Concern.	
	· PBT: Persistent, bioaccumulable and toxic substances.	
	<ul> <li>vPvB: Very persistent and very bioaccumulable substances.</li> <li>VOC: Volatile Organic Compounds.</li> </ul>	
	· DNEL: Derived No-Effect Level (REACH).	
	· PNEC: Predicted No-Effect Concentration (REACH).	
	· LC50: Lethal concentration, 50 percent.	
	LD50: Lethal dose, 50 percent.	
	<ul> <li>· UN: United Nations Organisation.</li> <li>· ADR: European agreement concerning the international carriage of dangeous goods by road.</li> </ul>	
	· RID: Regulations concerning the international transport of dangeous goods by rail.	
	· IMDG: International Maritime code for Dangerous Goods.	
	· IATA: International Air Transport Association.	
	· ICAO: International Civil Aviation Organization.	
	SAFETY DATA SHEET REGULATIONS:	70
	Safety Data Sheet in accordance with Article 31 of Regulation (EC) No. 1907/2006 (REACH) and Annex of Regulation (EU) No. 2020/8	78.
	HISTORIC: REVISION:	
	Version: 14 29/04/2020	
	Version: 15 02/01/2023	

<b>R</b> isa	VAMAR LISO (CE) Code : 4450		
ersion: 15	Revision: 02/01/2023	Previous revision: 29/04/2020	Date of printing: 02/01/20
Changes tha Sheet to Re	gulation (EU) No. 2020/878: All se	ect to the previous version due to the structural and conten actions.	
nditions are beyond ndling instruction. It islation. The information	our knowledge and control. The p is always the responsibility of the	ne present state of knowledge and on current UE and nation roduct is not to be used for other purposes than those spec user to take all necessary steps in order to fulfil the demand neant as a description of the safety requirements of the pro	sified, without first obtaining writter d laid down in the local rules and